math_of_money
Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Takeda Pharmaceutical Company
10-01-2017, 01:17 PM,
Post: #1
Takeda Pharmaceutical Company
Start a new thread for Takeda.

Takeda to Acquire ARIAD Pharmaceuticals, Inc.
Highlights :
* Highly strategic deal which transforms global oncology portfolio and pipeline by expanding into solid tumors and reinforcing existing strength in hematology
* Accretive to Takeda’s Underlying Core Earnings by FY2018 and generates immediate and long-term revenue growth
* Attractive value drivers include two very innovative precision medicines, Iclusig (ponatinib) and brigatinib, an exciting early stage pipeline and cost synergies
* Takeda will leverage ARIAD’s research and development capabilities and platform
* Takeda retains financial flexibility with no impact on dividend policy

More details in http://infopub.sgx.com/FileOpen/E-PressR...eID=435316

- Iclusig is a globally commercialized product with continued strong sales growth potential
- Brigatinib approval in the U.S. is expected in the first half of 2017, with peak sales potential over $1 billion and the potential to be the best-in-class ALK inhibitor
Specuvestor: Asset - Business - Structure.

http://www.valuebuddies.com
Website Find Reply
10-01-2017, 02:13 PM,
Post: #2
RE: Takeda Pharmaceutical Company
(10-01-2017, 01:17 PM)cyclone Wrote: Start a new thread for Takeda.

Takeda to Acquire ARIAD Pharmaceuticals, Inc.
Highlights :
* Highly strategic deal which transforms global oncology portfolio and pipeline by expanding into solid tumors and reinforcing existing strength in hematology
* Accretive to Takeda’s Underlying Core Earnings by FY2018 and generates immediate and long-term revenue growth
* Attractive value drivers include two very innovative precision medicines, Iclusig (ponatinib) and brigatinib, an exciting early stage pipeline and cost synergies
* Takeda will leverage ARIAD’s research and development capabilities and platform
* Takeda retains financial flexibility with no impact on dividend policy

More details in http://infopub.sgx.com/FileOpen/E-PressR...eID=435316

- Iclusig is a globally commercialized product with continued strong sales growth potential
- Brigatinib approval in the U.S. is expected in the first half of 2017, with peak sales potential over $1 billion and the potential to be the best-in-class ALK inhibitor

After failing to buy Salix from Valeant, they're feeling the heat to buy SOMETHING to cover the loss of earnings from loss of exclusivity from their branded drugs.

Find Reply


Forum Jump:


Users browsing this thread: 1 Guest(s)
Valuebuddies.com | Return to Top | | Lite (Archive) Mode | RSS Syndication | CONTACT US: nas......@valuebuddies.com |